---
figid: PMC9623415__fendo-13-1010092-g002
pmcid: PMC9623415
image_filename: fendo-13-1010092-g002.jpg
figure_link: /pmc/articles/PMC9623415/figure/f2/
number: Figure 2
figure_title: ''
caption: 'Pathways involved in JIMT-1 trastuzumab resistance (log2 FC normalized to
  SKBR3 signals). AFISimilarly expressed protein: light grey; antibody not available/poor
  performance: no fill; overexpressed total protein ≥ 1.5-fold (log2 FC ≥ 0.58): light
  orange; ≥ 2-fold: *; under-expressed total protein ≤0.67 (log2 FC ≤ -0.58): light
  green; ≤ 0.5-fold: *; overexpressed phosphosite ≥ 1.5-fold: orange; ≥ 2-fold: *;
  underexpressed phosphosite ≤ 0.67: green; ≤ 0.5-fold: *; predicted active protein:
  dark red outline; predicted inactive protein: dark blue outline.'
article_title: PKC-mediated phosphorylation and activation of the MEK/ERK pathway
  as a mechanism of acquired trastuzumab resistance in HER2-positive breast cancer.
citation: Jeanesse Scerri, et al. Front Endocrinol (Lausanne). 2022;13:1010092.
year: '2022'

doi: 10.3389/fendo.2022.1010092
journal_title: Frontiers in Endocrinology
journal_nlm_ta: Front Endocrinol (Lausanne)
publisher_name: Frontiers Media S.A.

keywords:
- acquired resistance
- breast cancer
- phospho-profile
- PKC/MEK/ERK
- signalosome
- HER2 positive
- patient stratification

---
